Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
September 3, 2024
-
BUSINESS Takeda Pushes Back Shipping Date as Trucker Overtime Cap Hits Logistics
September 2, 2024
-
BUSINESS AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
-
REGULATORY MHLW to Seek Nearly 800 Million Yen to Boost New Modalities: FY2025 Budget Request
August 29, 2024
-
REGULATORY Japan Approves Label Expansions for Alecensa, Nucala and More
August 29, 2024
-
BUSINESS Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
-
REGULATORY High-Dose Mecobalamin Now in Line to Become Japan’s 1st ALS Med in 9-Plus Years
August 28, 2024
-
ACADEMIA A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
-
BUSINESS A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
August 27, 2024
-
REGULATORY MHLW to Address Drug Loss, Generic Industry Reform in FY2025 Budget Request
August 26, 2024
-
BUSINESS Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
August 23, 2024
-
BUSINESS A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
-
COMMENTARY Japan’s Drug-Loss Landscape Is Transforming Driven by Private Sector
August 21, 2024
-
BUSINESS Bayer Set to Finally List Xarelto AG in December, Espha as Distributor
August 20, 2024
-
REGULATORY Japan Approves Equa, Onglyza Generics towards December Listing, 1st DPP-4 Copycat on Horizon?
August 19, 2024
-
ACADEMIA As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
August 9, 2024
-
REGULATORY Chuikyo Disappointed over Industry Survey on 2024 Drug Pricing Reform
August 8, 2024
-
REGULATORY Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
August 8, 2024
-
REGULATORY Dupixent Braces for Third Re-Pricing, LEO/Lilly Meds Face Spillover Cuts
August 8, 2024
-
REGULATORY AstraZeneca’s Tezspire to Face 4.1% CEA Price Cut in November
August 8, 2024
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…